From the Desk of Steve Strazza and Alfonso Depablos
Today’s most significant insider transaction comes in a Form 4 filing by Decheng Capital Management, a hedge fund focused on investing in early-stage life science companies.
Decheng reported a purchase in the biotech company Alpine Immune Sciences $ALPN worth more than $4.6 million.